Schwab Network on $PFE

Channel profile →Sources cited by the channel: BFA and JP Morgan, Baird, Bank of America, Barclays, Berenberg, Bernstein, Bernstein, with a Jefferies target cut noted, Bilal Little, Bird (analyst firm), CEO, CEO Joe Dominguez, Caner, Citi, Citigroup, Citizens, Daiwa, Dan Deming and Michael Monahan, Dan Ies; Morgan Stanley, Dan Ives, Dan Ives and unnamed analysts, Deutsche Bank, Erit Research, Evercore ISI, Evercore ISI; Dan Ives, Goldman Sachs, JP Morgan Chase, JPMorgan, JPMorgan Chase, James Demerard of Wall Street Research, Jefferies, Jefferies, UBS and Citigroup, Jensen Huang; Dan Ives, KeyBank, Loop Capital, Mattie Natsson, Michael Saylor, Milius (analyst), Morgan Stanley, Northrop, Oppenheimer, Oppenheimer, Freedom Broker, Oracle, PFA analysts, Quantum CEO, RBC, Reddit CEO, Rothschild Redburn, SK Hynix, Seth, Tim Bigham, Tim and KG, Truist, UBS, Wall Street Journal, Wedbush, Wells Fargo, analysts, the street2 entries

Schwab Network has discussed $PFE in 2 videos since 2026-09-02. The latest, on 2026-11-02, was bullish.

2026-11-02Bullish
“Ted Weisberg on META Value Opportunity in AI, Going Long on Energy & Airlines”
AI summary · Pfizer is a good stock to keep: a strong company with a good balance sheet, and its big dividend pays investors while they wait. It has historically been dull and is far behind the big pharmaceutical group, which has done great work recently, in the value-versus-tech contrast.

And Pfizer, you know, was forever dull. Pharmaceutical companies, big pharmaceutical companies, have been doing great work recently. Once again, value versus tech, and I think Pfizer is far behind this group.

It pays big dividends, so you're getting money while you wait. Strong company, good balance sheet. I think this is a good stock to keep.

2026-09-02Bullish
“Hayes: "950 Billion Reasons" to Buy Bonds, PFE & XRAY Buy Opportunities”
AI summary · PFE is a buy; downside protected by 6% yield and priced-in bad news, upside from oncology and GLP-1 pipeline.

I love it because it's so out of favor you can't give the stock away. Um you're getting a 6% dividend yield while you wait for them to turn the boat. They had a COVID windfall.

They used the money to buy CGEN 43 billion. That's going to do10 billion dollars a year. They cut 7.2 billion in cost. People are afraid of the loss of exclusivity from some of their major drugs.

It's lower than expected. And they have a GLP1 with the Metera coming out uh 2728, which is once a month GLP uh which you can take as a pill and subcutaneous. So maybe they'll be late to the party, maybe it'll be revolutionary.

We don't know. But in the meantime, costs are out. The oncology franchise pipeline is robust. All the bad news is priced in. You you got you're you know, I learned early on in this business, if your downside is protected, your upside will take care of itself.

And if I'm paid 6% to wait while this thing, you know, uh recovers over time. That's a good thing, not a bad thing.